The series B funding will enable Nuon Therapeutics to advance its orally active lead compound, tranilast, through Phase II clinical trials and support the discovery and development of additional compounds. Nuon Therapeutics’s strategy is to develop tranilast in new clinical indications covered by its intellectual property, as well as build a portfolio of additional drugs in autoimmune disease and pain.
Rodney Pearlman, CEO of Nuon Therapeutics, said: “We are pleased to have such a well-regarded syndicate of investors backing our development activities. These firms have extensive experience with biotechnology companies at our stage and we look forward to utilizing their expertise and support as we move tranilast into new clinical applications.”